



**Purdue Pharma L.P.**

One Stamford Forum  
Stamford, CT 06901-3431  
[www.purduepharma.com](http://www.purduepharma.com)

January 29, 2021

**VIA E-MAIL AND COURIER**

The Honorable Carolyn Maloney  
Chairwoman  
Committee on Oversight and Reform  
United States House of Representatives  
2157 Rayburn House Office Building  
Washington, D.C. 20515

Dear Chairwoman Maloney:

Thank you for the questions for the record from the Committee on Oversight and Reform's December 17, 2020 hearing titled "The Role of Purdue Pharma and the Sackler Family in the Opioid Epidemic." Purdue has enclosed a responsive presentation and would be happy to schedule an oral briefing with your staff to provide further context if necessary. We respectfully request that the Committee keep this presentation confidential and provide Purdue with advance notice should it decide to make the presentation public.

The public benefit company ("PBC") concept is currently authorized by more than 30 states and the District of Columbia. PBCs must include in their charter one or more specific public benefits as their statement of purpose, as opposed to typical boilerplate language authorizing a corporation to operate in furtherance of "any lawful purpose." This incorporates a PBC's mission in its founding document and provides a framework for addressing the company's business decisions. The specific PBC framework contemplated by Purdue was originally developed by lawyers for the Company. Based upon an initial review, we believe the requested documents are largely privileged. We are nevertheless open to providing an oral briefing if that would be of interest to the requesting Representative.

Additionally, we appreciate the opportunity to clarify an issue that may not have been clear to Members, given the lag and crosstalk over the WebEx transmission of the hearing. During his questioning of Dr. Landau, Representative Krishnamoorthi inquired about a draft presentation slide regarding responsibility for opioid-related deaths. The relevant exchange and crosstalk are reflected as follows in an unofficial transcript:

LANDAU:  
It was material in preparation for (INAUDIBLE)–

KRISHNAMOORTHY:  
–So you don't feel responsible, is that what you're saying?

LANDAU:  
Absolutely not, is what I'm saying.

KRISHNAMOORTHY:  
–Oh, okay. Very good.

LANDAU:  
**(INAUDIBLE)**—

Dr. Landau's response bolded above was, in fact, audible. Review of the audio and video recordings of the hearing confirms that Dr. Landau responded, "That's absolutely not what I'm saying." See 1:50:31-1:50:42 on the video available here: <https://oversight.house.gov/legislation/hearings/the-role-of-purdue-pharma-and-the-sackler-family-in-the-opioid-epidemic>

Further, a subsequent response by Dr. Landau to Representative Krishnamoorthi is recorded as, ". . . But I do believe that the product has helped a great many individuals suffering from pain, individuals who the medicine *wasn't* developed for and intended for." (Emphasis added.) However, review of the audio and video recordings of the hearing confirms that Dr. Landau stated ". . . a great many individuals suffering from pain, individuals who the medicine *was* developed for and intended for." It appears that Dr. Landau started to say "was intended" before expanding his testimony, and the reporter mis-recorded "was in . . ." as "wasn't." See video at 1:52:34-1:52:45.

Purdue respectfully requests that these errors in transcription, which alter the substance of Dr. Landau's testimony, not be reflected in the official transcript of the hearing.

Respectfully,



Matthew O'Donnell  
Executive Director, Head of Government Affairs & Public Policy  
Purdue Pharma L.P.

cc: The Honorable James R. Comer, Ranking Member

Enclosure

**Questions for the Record Hearing on “The Role of Purdue Pharma and the Sackler Family in the Opioid Epidemic”**

**December 17, 2020**

**Questions from Congressman Jamie Raskin for  
Craig Landau, President and CEO, Purdue Pharma L.P.**

---

1. **At the hearing, you testified that Purdue announced a plan to “dedicate 100 percent of Purdue’s assets, and resources, and capabilities, and know-how to the American people in the form of a public benefit company.”**
  - a. **Please provide to the Committee all documents created by Purdue, or by others on behalf of Purdue or for Purdue’s benefit, that describe the public benefit company plan, including but not limited to the design of the company, how the company will be structured, owned, controlled, and operated, the company’s plans to continue manufacturing OxyContin, and the company’s plans to manufacture or otherwise provide or support access to medicine to treat addiction and to reverse opioid overdoses; and**

Please find enclosed a presentation that provides an overview of the settlement proposal currently under consideration and includes information regarding the plan to transform Purdue into a public benefit company.

- b. **Please provide to the Committee all communications, including communications between Purdue executives or employees and members of the Sackler family, referring or relating to the public benefit company plan, including but not limited to the design of the company, how the company will be structured, owned, controlled, and operated, the company’s plans to continue manufacturing OxyContin, and the company’s plans to manufacture or otherwise provide or support access to medicine to treat addiction and to reverse opioid overdoses.**

Based on a review of readily available information, Purdue has determined that communications with members of the Sackler family related to the proposed public benefit company plan were generally made through counsel and that the idea to transform Purdue into a public benefit company was originally developed by lawyers for the Company.